Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 2

Evaluation of serum CXC chemokine ligand 16 (CXCL16) as a novel inflammatory biomarker or familial Mediterranean fever disease

Pages
813–818
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Logistic regression analysis indicated that high CXCL16 and erythrocyte sedimentation rate levels were predictive parameters for FMF disease (OR 8.31; 95% CI 2.59-26.62; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Familial Mediterranean fever (FMF) is a disease that is mainly diagnosed with clinical features.
📊
Key Findings & Data:Several wellknown inflammatory markers increase in FMF.
💡
Conclusion & Impact:Logistic regression analysis indicated that high CXCL16 and erythrocyte sedimentation rate levels were predictive parameters for FMF disease (OR 8.31; 95% CI 2.59-26.62; p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Familial Mediterranean fever (FMF) is a disease that is mainly diagnosed with clinical features. Several wellknown inflammatory markers increase in FMF. However, there is still a need for diagnostic tests for specifying FMF and monitoring inflammatory activity. CXCL16 is a chemokine produced by inflammatory cells that demonstrate efficacy in the acute phase response. In this study, we aimed to investigate the relationship between CXCL16 levels and FMF disease and to evaluate CXCL16 levels as a novel biomarker for FMF. Materials and methods: Fifty-three male patients diagnosed with FMF and sixty healthy individuals were included in this crosssectional study. Blood samples were taken in the first 24 h of the attack periods. Serum soluble CXCL16 was evaluated by enzyme-linked immunosorbent assay (ELISA) method. Results: CXCL16 (P < 0.001), erythrocyte sedimentation rate (P < 0.001), C-reactive protein (P < 0.001), and fibrinogen (P = 0.005) were significantly higher in FMF group than in control group. Receiver operating characteristic (ROC) curve analysis revealed a cut off value of CXCL16 as 2.68 ng/ml with 83% sensitivity and 68% specificity (P < 0.001). Logistic regression analysis indicated that high CXCL16 and erythrocyte sedimentation rate levels were predictive parameters for FMF disease (OR 8.31; 95% CI 2.59-26.62; p

🔖

Cite This Article

TANOĞLU, A., DÜZENLİ, T., AKYOL, T. (2022). Evaluation of serum CXC chemokine ligand 16 (CXCL16) as a novel inflammatory biomarker or familial Mediterranean fever disease. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 2, 813–818. https://ajindex.com/articles/609504

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nature Reviews Rheumatology 2014
  2. doi: 10.1038/nrrheum.2013.174 2. Alghamdi M. Familial Mediterranean fever, review of the literature. Clinical Rheumatology 2017
  3. 36 (8): 1707‐1713. doi:10.1007/s10067-017-3715-5 3. Özen S, Batu ED, Demir S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Frontiers in Immunology 2017
  4. doi:10.3389/fimmu.2017.00253 4. Ozdogan H, Ugurlu S. Familial Mediterranean fever. Presse Medicale (Paris, France: 1983) 2019
  5. 48(1 Pt 2): e61‐e76. doi:10.1016/j.lpm.2018.08.014 5. Kucuk A, Gezer IA, Ucar R, Karahan AY. Familial Mediterranean fever. Acta Medica (Hradec Kralove) 2014
  6. 57 (3): 97‐104. doi:10.14712/18059694.2014.47 6. Van Gorp H, Huang L, Saavedra P, Vuylsteke M, Asaoka T et al. Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever. Annals of the Rheumatic Diseases 2020
  7. 79 (7): 960-968. doi:10.1136/annrheumdis-2019-216701 7. Toplak N, Frenkel J, Ozen S, Lachmann HJ, Woo P et al. An international registry on autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases 2012
  8. 71 (7): 1177-1182. doi:10.1136/annrheumdis-2011-200549 8. Hassan AM, Farghal NMA, Hegab DS, Mohamed WS, Abd-Elnabi HH. Serum-soluble CXCL16 in juvenile systemic lupus erythematosus: a promising predictor of disease severity and lupus nephritis. Clinical Rheumatology 2018
  9. 37(11): 3025‐3032. doi:10.1007/s10067-018-4203-2 9. Lehrke M, Konrad A, Schachinger V, Tillack C, Seibold F et al. CXCL16 is a surrogate marker of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2008
  10. 43(3): 283‐288. doi:10.1080/00365520701679249 10. Yilmaz S, Cinar M, Pekel A, Simsek I, Musabak U et al. The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with Behçet’s disease. Clinical and Experimental Rheumatology 2013
  11. 31(3 Suppl 77): 84‐87 11. Gong Q, Wu F, Pan X, Yu J, Li Y et al. Soluble C-X-C chemokine ligand 16 levels are increased in gout patients. Clinical Biochemistry 2012
  12. 45(16-17): 1368-1373. doi: 10.1016/j.clinbiochem.2012.05.014 12. Qin M, Guo Y, Jiang L, Wang X. Elevated levels of serum sCXCL16 in systemic lupus erythematosus
  13. potential involvement in cutaneous and renal manifestations. Clinical Rheumatology 2014
  14. 33(11): 1595‐1601. doi:10.1007/s